Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
L Peyrin-Biroulet, WJ Sandborn… - Therapeutic …, 2021 - journals.sagepub.com
In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era
for inflammatory bowel disease, leading to marked improvements in treatment options and …
for inflammatory bowel disease, leading to marked improvements in treatment options and …
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies
F Magro, F Portela - BioDrugs, 2010 - Springer
Inflammatory bowel disease (IBD), most commonly referring to Crohn's disease and
ulcerative colitis, is a chronic and disabling condition with an increasing incidence in …
ulcerative colitis, is a chronic and disabling condition with an increasing incidence in …
Integrating anti–tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives
ME Blam, RB Stein, GR Lichtenstein - Official journal of the …, 2001 - journals.lww.com
Crohn's disease and ulcerative colitis are two idiopathic inflammatory disorders of the GI
tract. Manifestations of disease can be severe and lead to long term therapy with a variety of …
tract. Manifestations of disease can be severe and lead to long term therapy with a variety of …
Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases
CM Olesen, M Coskun, L Peyrin-Biroulet… - Pharmacology & …, 2016 - Elsevier
Biological treatment with tumor necrosis factor (TNF) inhibitors is successful in the
management of inflammatory bowel disease (IBD). All TNF inhibitors antagonize the pro …
management of inflammatory bowel disease (IBD). All TNF inhibitors antagonize the pro …
Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us?
AA Akobeng, WJ Sandborn, SJ Bickston… - Inflammatory bowel …, 2014 - academic.oup.com
In 1998, the US Food and Drug Administration granted regulatory approval to the first tumor
necrosis factor-α antagonist, infliximab, for the treatment of moderately to severely active …
necrosis factor-α antagonist, infliximab, for the treatment of moderately to severely active …
Novel pharmacological therapy in inflammatory bowel diseases: beyond anti-tumor necrosis factor
Inflammatory bowel diseases (IBDs) are chronic conditions of the gastrointestinal tract in
which dysregulated immune responses cause persistent inflammation of the gut mucosa …
which dysregulated immune responses cause persistent inflammation of the gut mucosa …
How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease
Introduction: Anti-tumor necrosis factor (TNF) agents have changed the therapeutic
approach to inflammatory bowel disease (IBD). However, a considerable proportion of …
approach to inflammatory bowel disease (IBD). However, a considerable proportion of …
[HTML][HTML] Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease
F Hoentjen, AA Van Bodegraven - World journal of …, 2009 - ncbi.nlm.nih.gov
Inflammatory bowel disease (IBD), in particular Crohn's disease refractory to conventional
therapy, fistulizing Crohn's disease and chronic active ulcerative colitis, generally respond …
therapy, fistulizing Crohn's disease and chronic active ulcerative colitis, generally respond …
Drug insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease
JT Chang, GR Lichtenstein - Nature clinical practice Gastroenterology & …, 2006 - nature.com
In the past decade, advances in the understanding of the pathogenesis of inflammatory
bowel disease have permitted the development of agents directed against rational …
bowel disease have permitted the development of agents directed against rational …
Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach
MJ Etchevers, I Ordás, E Ricart - Drugs, 2010 - Springer
Crohn's disease is a chronic, disabling, inflammatory condition of the gastrointestinal tract
that has a segmental distribution and can affect the entire gastrointestinal tract. Treatment of …
that has a segmental distribution and can affect the entire gastrointestinal tract. Treatment of …